Cervomed Inc CRVO

$2.29 -0.02 (-0.87%)

Valuation

Market cap
34,925,000
Revenue TTM
$4,010,000
Net income TTM
$-26,970,000
PE ratio
0.00
Forward PE
—
Profit margin
-672.57%
Debt to equity
0.00

Trading

Volume
136,000
Avg volume
276,682
Day's range
$2.28 – $2.41
Shares out
15,119,000
Stochastic %K
13%
Beta
-0.75
Analysts
Strong Sell
Price target
$18.00

Price

Company profile

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease...

Show more

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 744 4400
Website
https://www.cervomed.com
Address
20 Park Plaza, Suite 424, Boston, United States

Latest news

Stocktwits

Will05UW Oct 20, 1:43 PM
$CRVO AI Statistics Analysis: Statistical extrapolation from the Phase 2b extension (and supporting Phase 2a) data indicates a high probability that a properly executed Phase 3 will meet its primary endpoint (change in CDR-SB), under the planned assumptions of optimized dosing and pure-DLB enrichment. This is not a guarantee, and real-world “human” variability substantially moderates the confidence interval. Bottom-line probability estimate (data-driven, not formal Bayesian posterior): Under successful execution of the planned design (optimized dosing achieving target exposure in the large majority, clean enrichment, standard trial quality), the probability of statistically significant benefit on CDR-SB is in the 70–85% range. This is higher than typical Phase 3 dementia programs because the Phase 2b extension effectively served a within-trial exposure–response confirmation in the exact population and endpoint planned for Phase 3.
1 replies
ibaian Oct 19, 5:13 PM
$CRVO LOOK AT SLN TODAY, PATIENCE IS REQUIRED WITH BIOTECH
2 replies
ibaian Oct 19, 5:13 PM
$CRVO SIMILIAR TO SLN MOVEMENT SOON
0 replies
Cherrrraaaayyyy Oct 19, 1:39 PM
$CRVO I wouldn't be surprised to see news this week. Pretty active company with updates.
2 replies
5layer Oct 16, 2:47 PM 0 replies
walker7782 Oct 16, 11:29 AM
$CRVO Not a long but wanted to provide clarity. “Shorts” aren’t in control here. Funds like Sabby act as financers of last resort: they provide guaranteed, immediate capital when public markets are closed to the company, but extract punitive structural terms—deeply discounted shares, heavy warrant coverage, and reset provisions—that protect the fund while shifting dilution and price suppression onto common shareholders. A PIPE (Private Investment in Public Equity) fund buys discounted shares/warrants directly from an issuer. Sabby suppresses CRVO via convertible arbitrage: shorting common stock into rallies to lock gains, then covering risk-free using discounted shares/warrants, capping upside at warrant walls. CRVO management is complicit and knew this outcome going in. They’re pretty much a Wall Street loan shark. A big run will be an uphill battle here. Wishing longs all the best though! It’s just important to understand what you’re up against.
4 replies
BPler Oct 16, 8:07 AM
$CRVO Mentioning "Some studies have already started to capture audio, including a phase 2 trial studying the drug neflamapimod in patients with PPA, which has gathered voice recordings to analyze for linguistic and acoustic metrics." https://neurologytoday.aan.com/doi/10.1097/01.wnt.0001288804.23898.57
0 replies
Doki0926 Oct 16, 7:46 AM
$CRVO idiot shits who think in three year phases!!!! FUCK YOUR MOTHER!!!! It should be minimum 20 NOWWW!!!! Fuck idiots!!!!
0 replies